Versant Venture Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.23M Hold
148,831
– – 7.55% 6
2026
Q2
$8.12M Hold
148,831
– – 4.99% 6
2026
Q1
$7.08M Hold
148,831
– – 5.01% 6
2025
Q4
$7.8M Hold
148,831
– – 5.17% 4
2025
Q3
$9.6M Sell
148,831
-349,727
-70% -$20.1M 4.54% 4
2025
Q2
$24.2M Hold
498,558
– – 29.52% 2
2025
Q1
$17M Hold
498,558
– – 28.18% 2
2024
Q4
$19.6M Hold
498,558
– – 22.62% 2
2024
Q3
$23.4M Hold
498,558
– – 36.84% 1
2024
Q2
$26.9M Hold
498,558
– – 34.84% 1
2024
Q1
$34M Hold
498,558
– – 32.95% 1
2023
Q4
$31.2M Hold
498,558
– – 8.03% 2
2023
Q3
$22.6M Hold
498,558
– – 12.03% 3
2023
Q2
$28M Hold
498,558
– – 33.2% 2
2023
Q1
$22.5M Hold
498,558
– – 47.01% 1
2022
Q4
$20.3M Hold
498,558
– – 41.93% 1
2022
Q3
$32.6M Hold
498,558
– – 55.55% 1
2022
Q2
$30.3M Hold
498,558
– – 46.45% 1
2022
Q1
$31.3M Hold
498,558
– – 31.24% 1
2021
Q4
$37.8M Hold
498,558
– – 20.21% 2
2021
Q3
$55.8M Sell
498,558
-10,000
-2% -$1.26M 23.11% 1
2021
Q2
$82.3M Sell
508,558
-1,046,402
-67% -$127M 27.28% 1
2021
Q1
$189M Sell
1,554,960
-1,485,502
-49% -$224M 36.92% 1
2020
Q4
$466M Sell
3,040,462
-591,194
-16% -$69.9M 48.34% 1
2020
Q3
$304M Sell
3,631,656
-551,408
-13% -$48.9M 55.59% 1
2020
Q2
$307M Sell
4,183,064
-22,551
-0.5% -$1.32M 44.16% 1
2020
Q1
$177M Hold
4,205,615
– – 48.6% 1
2019
Q4
$256M Sell
4,205,615
-28,255
-0.7% -$1.54M 77.19% 1
2019
Q3
$174M Sell
4,233,870
-15,018
-0.4% -$718K 67.15% 1
2019
Q2
$200M Hold
4,248,888
– – 58.31% 1
2019
Q1
$152M Buy
4,248,888
+640,014
+18% +$22.1M 50% 1
2018
Q4
$103M Hold
3,608,874
– – 51.04% 1
2018
Q3
$160M Hold
3,608,874
– – 54.44% 1
2018
Q2
$212M Sell
3,608,874
-997,368
-22% -$56.8M 66.16% 1
2018
Q1
$211M Buy
+4,606,242
New +$190M 67.34% 1

Other funds holding CRSP

Versant Venture Management's CRSP Position: Q3 2026 in Review

Versant Venture Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 148,831 shares worth $8.23M. The position accounts for 7.55% of the portfolio, ranked #6.

Versant Venture Management first reported a position in CRSP in Q1 2018 and has held it in 35 quarters since. The position peaked at $466M in Q4 2020. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Versant Venture Management held 148,831 shares of CRISPR Therapeutics worth $8.23M as of Q3 2026.
  • Versant Venture Management left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up 7.55% of Versant Venture Management's portfolio in Q3 2026, its #6 holding.
  • Versant Venture Management first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 35 quarters since.
  • Versant Venture Management's CRISPR Therapeutics position peaked at $466M in Q4 2020.
  • 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Versant Venture Management's 13F filing for Q3 2026, filed 13 Nov 2026.